| Autor: |
Lodz, Noor Aliza, Mat Tamizi, Nurdiyana Farhana, Abd Mutalip, Mohd Hatta, Ganapathy, Shubash Shander, Lin, Chong Zhuo, Ismail, Rohani, Ahmad, Noor Ani |
| Předmět: |
|
| Zdroj: |
Asia-Pacific Journal of Public Health; Jan2024, Vol. 36 Issue 1, p96-103, 8p |
| Abstrakt: |
Monitoring SARS-CoV-2 antibody levels can provide insights into a person's immunity to COVID-19 and inform decisions about vaccination and public health measures. Anti-S may be useful as an indicator of an effective immune response. Thus, we conducted this study that aimed to determine the immune response of anti-S antibodies against SARS-CoV-2 for all the vaccine types over time among adult recipients in Malaysia and to determine the associated factors. This study was a cohort that recruited 2513 respondents aged 18 years and above from June to December 2021. Each participant was followed-up for 1-year period from the initial vaccine dose (baseline). We found that the anti-S antibody generally increased for all vaccine types and peaked at two weeks after the second dose vaccination, with Pfizer recipients having the highest median of 100 (100.00-100.00). During the third-month follow-up, the seropositivity of anti-S antibody and the median level decreased for all vaccines. We found that type of vaccines, comorbid status, infection, and booster status were significantly associated with the anti-S antibody level after one year. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
